Kalydeco Approval Widened for More Types of Cystic Fibrosis

THURSDAY, May 18, 2017 — The U.S. Food and Drug Administration says it has expanded approval for the cystic fibrosis drug Kalydeco (ivacaftor) to include 33 mutations of the disease, up from the previous 10 mutations.
In a media release, the agency…
Source: Topamax